Genpharmasec (531592)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Revenue momentum: 369.69% sales growth and latest quarter sales of ₹40 Cr indicate strong business activity and scale.
• Balance-sheet support: Book value ₹1.27 and P/B of 1.80, while not cheap, provide a tangible asset floor.
• Positive albeit modest returns: ROE 4.38% and ROCE 3.35% are positive, unlike a structurally loss-making business.
• Market positioning: Stock near its 52-week high of ₹2.29 reflects improving investor sentiment.

Concerns

• Unprofitable operations: Latest quarter net loss of ₹1 Cr and profit growth of -209.21%; P/E of 0.00 indicates no earnings to value.
• Weak fundamentals: ROE of 4.38% and ROCE of 3.35% are far below attractive levels for a small-cap distributor, and Piotroski F-Score is weak at 4/9.
• Transparency gaps: Promoter holding and debt/equity are N/A, making it difficult to assess governance and leverage.
• No return to shareholders: Dividend yield is 0.00%, so returns rely entirely on speculative price appreciation.

AI Analysis

At ₹2.29, Genpharmasec has a market cap of ₹129 crore. When I see sales growth of 369.69%, my attention is piqued, but a value investor must look through the windshield, not the rearview mirror. The latest quarter shows ₹40 crore in sales, yet the company lost ₹1 crore. Profit growth is down 209.21%, and the P/E is effectively zero—not because earnings are magnificent, but because earnings are absent. This is a trading and distribution business, an industry with inherently thin moats and limited pricing power. There is no evidence of durable competitive advantage. Turning to balance-sheet metrics, book value is ₹1.27, so the stock trades at 1.8 times book. That may not look extreme, but for a business earning only 4.38% ROE and 3.35% ROCE, the premium is hard to justify. The Piotroski F-Score of 4/9 tells me the financial health is weak. No dividend is paid. I also notice that promoter holding and debt-equity data are not available; in India, missing ownership information is a red flag for a small-cap. With the FairStock score insufficient, I have more questions than answers. Could Genpharmasec become a turnaround? Yes, if this revenue surge converts into sustained profits and returns. But I don't pay today's price for tomorrow's hope. The evidence today is of a loss-making, low-return distributor selling at a premium to book. That's speculation, not investment. I will watch from the sidelines until the earnings and governance picture improves.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer